7 results about "Polysorbates" patented technology

The invention discloses a self-emulsifying adjuvant of a vaccine and a preparation method of the self-emulsifying adjuvant, and relates to the technical field of vaccine adjuvants. The adjuvant comprises an oil phase, an emulsifier and a freeze-drying protective agent, the oil phase comprises squalene and tocopherol, the emulsifier comprises polysorbate and a polyoxyethylene-polyoxypropylene block copolymer, and the freeze-drying protective agent comprises sugar and sugar alcohol. The preparation method comprises the following steps: emulsifying an oil phase and a water phase to form a nano-emulsion, and then freeze-drying to obtain freeze-dried powder. The adjuvant has the advantages of small particle size, uniform distribution, high stability, rapid reconstruction and the like, and can effectively maintain active components and improve the immune effect of vaccines.

The present invention is directed to methods for treating or preventing neuroinflammation in a subject by administering an effective amount of a single-domain antibody (sdAb) comprising SEQ ID NO:1. The method is applicable to subjects with multiple sclerosis, including secondary progressive, primary progressive, and relapsing-remitting forms. Administration may be intravenous, subcutaneous, or intrathecal, with dosage regimens including daily administration, loading and maintenance doses, or continuous infusion. The method may be initiated upon first clinical signs of central nervous system demyelination and continued for at least 14 days. The sdAb may be co-administered with a pharmaceutically acceptable excipient such as mannitol, sucrose, or polysorbate 80, and optionally combined with disease-modifying therapies including interferon-β, glatiramer acetate, fingolimod, or ocrelizumab. The invention provides a targeted approach for modulating neuroinflammatory processes in neurological disorders.

The invention relates to the technical field of biological medicines, in particular to an IgG4 monoclonal antibody pharmaceutical preparation as well as a preparation method and application thereof. The invention provides an IgG4 monoclonal antibody pharmaceutical preparation. The IgG4 monoclonal antibody pharmaceutical preparation comprises an IgG4 monoclonal antibody, poloxamer 188 and a pharmaceutically acceptable buffer solution. The research system evaluates the feasibility of replacing the traditional polysorbate by the poloxamer 188 for stabilizing the IgG4 monoclonal antibody. By combining thermodynamic analysis, interfacial property determination and multi-stress model experiments, the stress dependency difference of a surfactant stabilization mechanism is researched and revealed, and an important theoretical basis is provided for reasonable selection of a stabilizer in a protein preparation.

The invention provides a perfluorohexanone stable emulsion based on a microchannel and a preparation method thereof, and belongs to the technical field of fire extinguishing agent preparation. The perfluorohexanone stable emulsion is in an oil-in-water type, an outer water phase wraps an oil phase, the oil phase is a perfluorohexanone phase, and the preparation and regulation of the perfluorohexanone stable emulsion are realized by adjusting the injection pump rates of the water phase and the perfluorohexanone phase; and the water phase comprises the following components: a polysorbate surfactant, alkylphenol polyoxyethylene ether, polyvinyl alcohol, deionized water and glycerol. The stable perfluorohexanone emulsion prepared by the invention continuously absorbs heat when being in contact with a combustible material, and effective cooling is finally realized. When the environment temperature rises, the water and the perfluorohexanone are vaporized and expanded, the expanded water vapor and perfluorohexanone steam occupy a combustion area and weaken air supply, the local oxygen volume fraction is reduced, and therefore the combustion intensity is reduced, and finally fire extinguishing is achieved.

The invention discloses a blending method for adjusting skin disease plaster according to humidity, and belongs to the technical field of plaster compositions.The method comprises the steps that under the preset temperature and humidity, polyethylene glycol is added into a mixture containing multiple matrixes in batches, a pre-prepared mixture of hydroxypropyl methyl cellulose and carbomer is added in three times, and the mixture is stirred to be uniform; performing variable-speed stirring to a transparent gel state; and slowly adding a mixture of polysorbate and polyoxyethylene sorbitan monooleate which are heated to a preset temperature into the colloidal mixture under the condition of controlling the temperature difference, and adding a trehalose aqueous solution for stirring to obtain the target paste. Through the scheme of the invention, the expansion degree fluctuation of the paste with different humidity can be reduced, and the stability is improved.

Provided are a moist-heat sterilized nimodipine composition free of ethanol and phospholipid and a method for preparing the same. The composition comprises (1) nimodipine; (2) a non-phospholipid surfactant selected from polyoxyethylene castor oil, polyoxyethylene hydrogenated castor oil, polyoxyl 15 hydroxystearate, D-alpha-tocopherol polyethylene glycol 1000 succinate (TPGS), polysorbates, glyceryl monocaprylocaprate, or any mixture of two or more thereof; and (3) a co-solvent, which is propylene glycol.

This invention relates to the field of ophthalmic formulation technology, specifically disclosing a long-lasting moisturizing contact lens lubricant and its preparation method. The lubricant comprises an oil phase component consisting of active liquid paraffin, a ceramide analog, and phytosterol polyoxyethylene ether-20; an aqueous phase component consisting of an osmotic pressure regulator and purified water; and a cationic agent and a composite surfactant dispersed at the interface. The composite surfactant is composed of polysorbate 80 and sucrose stearate, and the dosage form is an oil-in-water nanoemulsion. Its preparation involves phase preparation, emulsification homogenization and interface control, stabilization treatment, and aseptic molding steps. The product exhibits good ocular compatibility, long-lasting moisturizing properties, and a stable emulsion system, significantly improving the comfort of contact lens wear.